| Targeting the gut and tumor microbiota in cancer EM Park, M Chelvanambi, N Bhutiani, G Kroemer, L Zitvogel, JA Wargo Nature medicine 28 (4), 690-703, 2022 | 321 | 2022 |
| STING agonists as cancer therapeutics A Amouzegar, M Chelvanambi, JN Filderman, WJ Storkus, JJ Luke Cancers 13 (11), 2695, 2021 | 291 | 2021 |
| Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome RC Simpson, ER Shanahan, M Batten, ILM Reijers, M Read, IP Silva, ... Nature medicine 28 (11), 2344-2352, 2022 | 139 | 2022 |
| STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment M Chelvanambi, RJ Fecek, JL Taylor, WJ Storkus Journal for immunotherapy of cancer 9 (2), e001906, 2021 | 117 | 2021 |
| Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells Y Goyal, GT Busch, M Pillai, J Li, RH Boe, EI Grody, M Chelvanambi, ... Nature 620 (7974), 651-659, 2023 | 107 | 2023 |
| Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy CP Vellano, MG White, MC Andrews, M Chelvanambi, RG Witt, ... Nature 606 (7915), 797-803, 2022 | 84 | 2022 |
| Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced … WJ Storkus, D Maurer, Y Lin, F Ding, A Bose, D Lowe, A Rose, M DeMark, ... Journal for immunotherapy of cancer 9 (11), e003675, 2021 | 42 | 2021 |
| STINGing the tumor microenvironment to promote therapeutic tertiary lymphoid structure development JN Filderman, M Appleman, M Chelvanambi, JL Taylor, WJ Storkus Frontiers in immunology 12, 690105, 2021 | 24 | 2021 |
| IL-36 signaling in the tumor microenvironment M Chelvanambi, AM Weinstein, WJ Storkus Tumor Microenvironment: The Role of Interleukins–Part A, 95-110, 2020 | 17 | 2020 |
| A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated … CL Roland, EF Nassif Haddad, EZ Keung, WL Wang, AJ Lazar, H Lin, ... Nature Cancer 5 (4), 625-641, 2024 | 14 | 2024 |
| Cutaneous melanoma: mutational status and potential links to tertiary lymphoid structure formation D Salem, M Chelvanambi, WJ Storkus, RJ Fecek Frontiers in Immunology 12, 629519, 2021 | 14 | 2021 |
| Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma S Ludwig, CS Hong, BM Razzo, KPL Fabian, M Chelvanambi, S Lang, ... Cancer Immunology, Immunotherapy 68, 1133-1141, 2019 | 14 | 2019 |
| Gut microbiome in patients with early-stage and late-stage melanoma RG Witt, SH Cass, T Tran, A Damania, EE Nelson, E Sirmans, EM Burton, ... Jama Dermatology 159 (10), 1076-1084, 2023 | 13 | 2023 |
| Monitoring and modulating diet and gut microbes to enhance response and reduce toxicity to cancer treatment A Knisely, YD Seo, JA Wargo, M Chelvanambi Cancers 15 (3), 777, 2023 | 13 | 2023 |
| Exercise training reduces the inflammatory response and promotes intestinal mucosa-associated immunity in lynch syndrome N Deng, L Reyes-Uribe, JF Fahrmann, WS Thoman, MF Munsell, ... Clinical Cancer Research 29 (21), 4361-4372, 2023 | 8 | 2023 |
| Loss-of-function mutations in PPP2R1A correlate with exceptional survival in ovarian clear cell carcinomas treated with immune checkpoint inhibitors (099) E Hinchcliff, A Patel, B Fellman, Y Yuan, M Chelvanambi, J Wargo, Y Liu, ... Gynecologic Oncology 166, S66, 2022 | 4 | 2022 |
| STING Agonists as Cancer Therapeutics. Cancers 2021, 13, 2695 A Amouzegar, M Chelvanambi, J Filderman, W Storkus, J Luke | 4 | |
| Immunotherapy response-associated Akkermansia: canary in a coal mine? T Cascone, M Chelvanambi, JA Wargo Trends in Immunology 43 (5), 337-339, 2022 | 3 | 2022 |
| MAdCAM-1: a newly identified microbial'gut check'for T cells. M Chelvanambi, JA Wargo Trends in Immunology, S1471-4906 (23) 00131, 2023 | 2 | 2023 |
| Mechanistic Investigation of Site-specific DNA Methylating Agents Targeting Breast Cancer Cells LL Lowder, M Powell, SE Miller, RJ Kishton, CB Kelly, CB Cribb, ... Journal of Medicinal Chemistry 64 (17), 12651-12669, 2021 | 2 | 2021 |
